Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms.

The aim of this study was to better understand the mass transport mechanisms involved in the control of drug release from lipid-based implants. Different types of triglyceride-based cylinders were prepared by compression. Glycerol-trilaurate, -trimyristate, -tripalmitate and -tristearate were used as model lipids, lysozyme and pyranine as model drugs. The effects of several formulation and processing parameters on the resulting drug release kinetics in phosphate buffer pH 7.4 were studied and the obtained results analyzed using Fick's second law of diffusion. Interestingly, lysozyme release from implants prepared by compression of a lyophilized emulsion (containing dissolved drug and lipid) was found to be purely diffusion-controlled, irrespective of the type of triglyceride. In contrast, the dominating release mechanism depended on the type of lipid in the case of pyranine-loaded implants prepared by compression of a lyophilized lipid-drug solution: with glycerol-trilaurate and -tristearate the systems were found to be purely diffusion-controlled, whereas also other mass transport phenomena are of importance in glycerol-trimyristate and -tripalmitate-based devices. Similarly, changes in the size of the compressed lipid-drug particles, drug loading and compression force significantly affected the underlying release mechanisms. The addition of a drug-free, poly(lactic-co-glycolic acid) (PLGA)-based coating around the implants delayed the onset of pyranine release for about 20 days. Interestingly, the subsequent drug release was purely diffusion-controlled, irrespective of the type of triglyceride. Also the addition of different amounts (and particle size fractions) of saccharose to pyranine-loaded implants led to purely diffusion-controlled drug release.

[1]  J. Westwater,et al.  The Mathematics of Diffusion. , 1957 .

[2]  Paul Y. Wang Lipids as excipient in sustained release insulin implants , 1989 .

[3]  Suming Li,et al.  Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence. , 1995, Biomaterials.

[4]  Jean-Maurice Vergnaud,et al.  Controlled Drug Release Of Oral Dosage Forms , 1993 .

[5]  J. Siepmann,et al.  Programmable implants--from pulsatile to controlled release. , 2006, International journal of pharmaceutics.

[6]  I. Tucker,et al.  The Release of Macromolecules from Fatty Acid Matrices: Complete Factorial Study of Factors Affecting Release , 1994, The Journal of pharmacy and pharmacology.

[7]  N. Medlicott,et al.  Melted glyceryl palmitostearate (GPS) pellets for protein delivery. , 2004, International journal of pharmaceutics.

[8]  Philippe Menei,et al.  Stereotaxic implantation of 5‐fluorouracil‐releasing microspheres in malignant glioma , 2004, Cancer.

[9]  A. Göpferich,et al.  Development and characterization of lipid microparticles as a drug carrier for somatostatin. , 2001, International journal of pharmaceutics.

[10]  S. Schwendeman,et al.  Comparison of the effects of Mg(OH)2 and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(D,L-lactide-co-glycolide) implants. , 2002, Biomaterials.

[11]  A. Mikos,et al.  In vitro degradation of thin poly(DL-lactic-co-glycolic acid) films. , 1999, Journal of biomedical materials research.

[12]  A. Göpferich,et al.  Lipid microparticles as a parenteral controlled release device for peptides. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[13]  P. Y. Wang,et al.  Palmitic acid as an excipient in implants for sustained release of insulin. , 1991, Biomaterials.

[14]  G. Winter,et al.  Continuous release of rh-interferon α-2a from triglyceride matrices , 2004 .

[15]  Richard Assaker,et al.  Local and Sustained Delivery of 5-Fluorouracil from Biodegradable Microspheres for the Radiosensitization of Malignant Glioma: A Randomized Phase II Trial , 2005, Neurosurgery.

[16]  G. Winter,et al.  Continuous Release of rh-Interferon α-2a from Triglyceride Implants: Storage Stability of the Dosage Forms , 2006, Pharmaceutical development and technology.

[17]  A. Gazzaniga,et al.  Monolithic Triglyceride Matrices: A Controlled-Release System for Proteins , 2003, Pharmaceutical development and technology.

[18]  A. Göpferich,et al.  Monolithic glyceryl trimyristate matrices for parenteral drug release applications. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[19]  J. Benoit,et al.  Local and sustained delivery of 5‐fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma , 1999, Cancer.